Jump to content
 







Main menu
   


Navigation  



Main page
Contents
Current events
Random article
About Wikipedia
Contact us
Donate
 




Contribute  



Help
Learn to edit
Community portal
Recent changes
Upload file
 








Search  

































Create account

Log in
 









Create account
 Log in
 




Pages for logged out editors learn more  



Contributions
Talk
 



















Contents

   



(Top)
 


1 Tests  



1.1  CH50 Procedure  





1.2  CH50 Interpretation  







2 References  














Total complement activity







Add links
 









Article
Talk
 

















Read
Edit
View history
 








Tools
   


Actions  



Read
Edit
View history
 




General  



What links here
Related changes
Upload file
Special pages
Permanent link
Page information
Cite this page
Get shortened URL
Download QR code
Wikidata item
 




Print/export  



Download as PDF
Printable version
 
















Appearance
   

 






From Wikipedia, the free encyclopedia
 


Total complement activity
Purposeassess the level of functioning of the complement system

Total complement activity (TCA) refers to a series of tests that determine the functioning of the complement system in an individual.

Tests[edit]

Complement tests
C4 (C) FB (A) C3 CH50 Conditions
· PSG, C3 NeF AA
· · HAE, C4D
· · · TCPD
·/↓ SLE
inflammation

A variety of tests can be used to measure TCA, but the most commonly used on is the CH50 test.[1][2] Other tests include the liposome immunoassay (LIA),[3] single tube titration method,[4] and the plate-hemolysis method.[5]

CH50 Procedure[edit]

The test is based on the capacity of an individual's serum to lyse sheep erythrocytes coated with anti-sheep antibodies (preferably rabbit IgG). The individual's serum is diluted until a minimum concentration of 50% of the sheep's red blood cells are lysed. This is recorded as the CH50.

CH50 tests the classical complement pathway and thus requires functioning C1-C9 factors.

CH50 Interpretation[edit]

If an individual has deficient or malfunctioning complement factors, then at a baseline they have decreased capacity to lyse the erythrocytes. Therefore, any dilution to their serum would further impair this functioning, meaning that a lower dilution needs to be reached to achieve 50% capacity. In contrast, any individual with increased complement levels or activity would have an elevated CH50 since increasing dilution would be necessary to reach the 50% lyse marking.

Decreased CH50 values may be seen in cirrhosisorhepatitis[6] as a result of impaired complement production in the liver. It can also be seen in systemic lupus erythematosus as a result of increased usage of complement factors due to the pathology of the autoimmune condition. It is decreased during attacks of hereditary angioedema (but those with the disease have a normal value in between attacks).[7]

Increased CH50 values means that their complement is hyperfunctional relative to normal, and this may be seen in cancerorulcerative colitis[citation needed].

One can interpret the CH50 value along with the individual's complement factor values to help determine the etiology. For example, if and individual has normal C3/C4 values but a decreased CH50, that can indicate a terminal complement pathway deficiency while if one has low C3 and CH50 values that can indicate an autoimmune condition such as systemic lupus erythematosus.

Alternative pathway hemolytic assay ("AH50") can be used in conjunction to indicate if there is a terminal pathway deficiency (CH50 and AH50 both are low), classical pathway deficiency (CH50 low, AH50 normal) or alternative pathway deficiency (AH50 low, CH50 normal).

References[edit]

  1. ^ Michael T. Lotze; Angus W. Thomson (2005). Measuring immunity: basic biology and clinical assessment. Academic Press. pp. 151–. ISBN 978-0-12-455900-4. Retrieved 3 December 2010.
  • ^ Costabile, Maurizio (March 29, 2010). "Measuring the 50% Haemolytic Complement (CH50) Activity of Serum". J. Vis. (37): e1923. doi:10.3791/1923. PMC 3168207. PMID 20351687.
  • ^ N, Souda (October 1998). "Studies on the conditions of blood sampling and storage for the liposome-based CH50 assay". The Japanese Journal of Clinical Pathology. 46 (10): 1049–1055. PMID 9816918.
  • ^ Hajime, K (1983). "A Simple Procedure for the Titration of Total Hemolytic Complement Activity". Japanese Journal of Clinical Chemistry. 12: 143–147. doi:10.14921/jscc1971b.12.2_143.
  • ^ Nilsson, U. R.; Nilsson, B. (1984-08-03). "Simplified assays of hemolytic activity of the classical and alternative complement pathways". Journal of Immunological Methods. 72 (1): 49–59. doi:10.1016/0022-1759(84)90432-0. ISSN 0022-1759. PMID 6747305.
  • ^ "Complement: MedlinePlus Medical Encyclopedia". medlineplus.gov. Retrieved 11 February 2017.
  • ^ Michael M Frank, MD (2018-08-30). "Hereditary Angioedema Workup". Medscape.

  • t
  • e

  • Retrieved from "https://en.wikipedia.org/w/index.php?title=Total_complement_activity&oldid=1198246277"

    Categories: 
    Complement system
    Immunologic tests
    Medical diagnostic stubs
    Hidden categories: 
    All articles with unsourced statements
    Articles with unsourced statements from February 2021
    All stub articles
     



    This page was last edited on 23 January 2024, at 15:53 (UTC).

    Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.



    Privacy policy

    About Wikipedia

    Disclaimers

    Contact Wikipedia

    Code of Conduct

    Developers

    Statistics

    Cookie statement

    Mobile view



    Wikimedia Foundation
    Powered by MediaWiki